Quellis Biosciences

Quellis was established with the mission to provide top-notch treatments to individuals afflicted by severe rare medical conditions – and those who are not sufficiently served by existing therapy alternatives. The organization is situated in Boston, and is spearheaded by individuals from the biotech startup Viridian LLC collaborating with the team at biotech accelerator Xontogeny LLC, backed by funding from the Perceptive Xontogeny Venture Fund. The Quellis team possesses extensive expertise in mAb exploration and advancement, establishment of companies, and private and public investments in biotechnology. Our collective objective is to develop impactful medications for every targeted ailment.